ProCE Banner Activity

Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma: 3.5-Year Follow-up of a Pooled Analysis of 3 Clinical Trials

Slideset Download
Conference Coverage

In this pooled analysis, median PFS was nearly 4 years and duration of response was nearly 4.5 years for those patients with relapsed/refractory MCL who achieved a CR with single agent ibrutinib therapy.

Released: December 13, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology